A systematic review and meta-analysis was carried out 17 to investigate the effectiveness of tumor necrosis factor-alpha inhibitors such as etanercept, infliximab, and adalimumab used as second line treatment in patients with RA. The gene discussed is TNF; the disease is rheumatoid arthritis.